RTTNews | Jan 5, 2022 11:50AM EST

11:50 Wednesday, January 5, 2022 (RTTNews.com) - Shares of Mainz Biomed B.V. (MYNZ) surged over 40% on Wednesday morning after the molecular genetics diagnostic company announced that it acquired exclusive rights to novel mRNA biomarkers.

MYNZ is currently trading at $14.76, up $4.44 or 43.02%, on the Nasdaq.

Mainz Biomed has entered into a Technology Rights Agreement with Socpra Sciences Sant Et Humaines S.E.C. to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the company's highly efficacious, and easy-to-use detection test for colorectal cancer.

Mainz is currently marketing ColoAlert in Europe through its unique business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. The Company is also preparing to initiate ColoAlert's regulatory pathway for approval in the United States.

Read the original article on RTTNews ( https://www.rttnews.com/3252984/why-are-mainz-biomed-shares-surging-over-40.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved